Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?

BACKGROUND: The NOV gene product, CCN3, has been reported in a diverse range of tumors to serve as a negative growth regulator, while acting as a tumor suppressor in Chronic Myelogenous Leukemia (CML). However, the precise mechanism of its silencing in CML is poorly understood. In the current study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Vatanmakanian, Mousa, Tavallaie, Mahmood, Ghadami, Shirin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480731/
https://www.ncbi.nlm.nih.gov/pubmed/31014357
http://dx.doi.org/10.1186/s12964-019-0350-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480731/
https://www.ncbi.nlm.nih.gov/pubmed/31014357
http://dx.doi.org/10.1186/s12964-019-0350-6

Ejemplares similares